Post-ASCT response and time to initiation of second-line therapy
| Post-ASCT response . | Time in months from ASCT to initiation of second-line therapy (number of patients) . | P . | ||||
|---|---|---|---|---|---|---|
| Group 1 . | Group 2 . | Group 3 . | Group 4 . | Group 5 . | ||
| ≥VGPR | ||||||
| Yes | 18.2 (10) | 36.6 (34) | 25.5 (47) | 47.2 (37) | <.05 | |
| No | 8.4 (10) | 17.7 (17) | 9.4 (24) | 15.3 (32) | 3.7 (9) | .01 |
| P | .11 | .004 | <.001 | <.001 | ||
| ≥PR | ||||||
| Yes | 17.0 (21) | 32.3 (47) | 23.6 (60) | 33.8 (62) | 12.2 (4) | .02 |
| No | 3.9 (3) | 24.5 (5) | 8.2 (16) | 10.9 (10) | 3.6 (6) | .01 |
| P | <.001 | .04 | <.001 | .01 | .08 | |
| Organ response | ||||||
| Yes | 24.3 (7) | 36.7 (29) | 35.4 (29) | 48.6 (35) | 19.3 (3) | .38 |
| No | 9.4 (17) | 26.8 (23) | 12.3 (47) | 22.3 (37) | 3.7 (7) | <.001 |
| P | .008 | .02 | <.001 | <.001 | .03 | |
| Post-ASCT response . | Time in months from ASCT to initiation of second-line therapy (number of patients) . | P . | ||||
|---|---|---|---|---|---|---|
| Group 1 . | Group 2 . | Group 3 . | Group 4 . | Group 5 . | ||
| ≥VGPR | ||||||
| Yes | 18.2 (10) | 36.6 (34) | 25.5 (47) | 47.2 (37) | <.05 | |
| No | 8.4 (10) | 17.7 (17) | 9.4 (24) | 15.3 (32) | 3.7 (9) | .01 |
| P | .11 | .004 | <.001 | <.001 | ||
| ≥PR | ||||||
| Yes | 17.0 (21) | 32.3 (47) | 23.6 (60) | 33.8 (62) | 12.2 (4) | .02 |
| No | 3.9 (3) | 24.5 (5) | 8.2 (16) | 10.9 (10) | 3.6 (6) | .01 |
| P | <.001 | .04 | <.001 | .01 | .08 | |
| Organ response | ||||||
| Yes | 24.3 (7) | 36.7 (29) | 35.4 (29) | 48.6 (35) | 19.3 (3) | .38 |
| No | 9.4 (17) | 26.8 (23) | 12.3 (47) | 22.3 (37) | 3.7 (7) | <.001 |
| P | .008 | .02 | <.001 | <.001 | .03 | |
At time of second-line therapy: group 1, early signs of recurrent disease that did not yet met either hematologic or organ R/P criteria; group 2 evidence of hematologic R/P without signs of organ R/P; group 3, evidence of organ R/P without hematologic R/P; group 4, both hematologic and organ R/P; and group 5, suboptimal response to ASCT and given second line as consolidation.